Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease

A. Selva-O’Callaghan, MD, PhD
F. Romero-Bueno, MD, PhD
E. Trallero-Araguás, MD, PhD
A. Gil-Vila, MD
J. C. Ruiz-Rodríguez, MD, PhD
O. Sánchez-Pernaute, MD, PhD
I. Pinal-Fernández, MD, PhD

Address
1,2Systemic Autoimmune Diseases Unit, Medicine Department, Vall d’Hebron University Hospital, GEAS Group, Universitat Autónoma de Barcelona, 08012 Barcelona, Spain
Email: a selva@vhebron.net
2Rheumatology Department, Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain
3Rheumatology Department, Vall d’Hebron University Hospital, GEAS Group, Barcelona, Spain
4Intensive Care Department, Vall d’Hebron University Hospital, Shock, Organ Dysfunction, and Resuscitation Research Group, Vall D’Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
5National Institutes of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, USA
6Johns Hopkins University School of Medicine, Baltimore, MD, USA
7Faculty of Health Sciences and Faculty of Computer Science, Multimedia and Telecommunications, Universitat Oberta de Catalunya, Barcelona, Spain

Published online: 28 September 2021
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021

Keywords Rapidly progressive interstitial lung disease · Inflammatory myopathy · Anti-MDA5 antibody · Clinically amyopathic dermatomyositis · Immunosuppressive therapy
Abstract

Purpose of the Review: Idiopathic inflammatory myopathies are a heterogeneous group of autoimmune disorders. The presence of different autoantibodies allows clinicians to define distinct phenotypes. Antibodies against the melanoma differentiation-associated protein 5 gene, also called anti-MDA5 antibodies, are associated with a characteristic phenotype, the clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease. This review aims to analyze the different pharmacological options for the treatment of rapidly progressive interstitial lung disease in patients with anti-MDA5 antibodies.

Recent Findings: Evidence-based therapeutic recommendations suggest that the best initial approach to treat these patients is an early combination of immunosuppressive drugs including either glucocorticoids and calcineurin inhibitors or a triple therapy adding intravenous cyclophosphamide. Tofacitinib, a Janus kinase inhibitor, could be useful according to recent reports. High ferritin plasma levels, generalized worsening of pulmonary infiltrates, and ground-glass opacities should be considered predictive factors of a bad outcome. In this scenario, clinicians should consider rescue therapies such as therapeutic plasma exchange, polymyxin-B hemoperfusion, veno-venous extracorporeal membrane oxygenation, or even lung transplantation.

Summary: Combined immunosuppressive treatment should be considered the first-line therapy for patients with anti-MDA5 rapidly progressive interstitial lung disease. Aggressive rescue therapies may be useful in refractory patients.

Introduction

Idiopathic inflammatory myopathies (IIM) are heterogeneous disorders of immunologic origin that affect multiple organs and systems, including the muscles, skin, lungs, and the joints [1••]. Around 70% of patients with IIM develop autoantibodies that can be categorized as myositis-specific antibodies (MSA) and myositis-associated antibodies (MAA). Myositis-associated antibodies can be detected in other autoimmune diseases whereas MSA are generally positive only in patients with myositis and mutually exclusive. The presence of MSA is of great support for the clinicians, allowing to differentiate between distinct myositis phenotypes [1••].

More than a third of patients with myositis have some type of interstitial lung disease (ILD) [2]. A proportion of those patients with myositis and ILD experience a rapidly progressive course. A new autoantibody, the anti-MDA5, described in 2005 by Sato et al. [3] and directed against the melanoma differentiated gene 5 protein (MDA5), also known as interferon-induced helicase C domain-containing protein 1 (IFIH1), is associated with the rapidly progressive course of the ILD.

Patients with anti-MDA5 autoantibodies show a clinical phenotype characterized by amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP-ILD) [4–7]. Other features such as skin ulcers, polyarthritis, or overt clinical myopathy are also described in patients with anti-MDA5 autoantibodies, but RP-ILD is by far the most severe manifestation of the disease [8].

This review aims to analyze the standard pharmacological options for the treatment of the RP-ILD associated with anti-MDA5 autoantibodies. Moreover, we also discuss aggressive therapeutic alternatives reserved as rescue therapy, such as plasmapheresis, polymyxin B-hemoperfusion, extracorporeal membrane oxygenation (ECMO), or lung transplantation.
Physiopathology—role of MDA5, interferon, and innate immunity

The MDA5/IFIH1 protein participates in a well-recognized innate antiviral response, unchaining the production of type I interferons upon detection of viral double-stranded RNA at the cytosol. Otherwise, the gain of function mutations in IFIH1 has been associated with a distinct spectrum of autoimmune or autoinflammatory states [9, 10].

MDA5 is a member of the retinoic-acid inducible gene (RIG)-I-like helicases, which act as cytoplasmic RNA sensors. MDA5-RNA virus complexes trigger the activation of mitochondrial antiviral proteins (MAVS), which enable nuclear translocation of interferon regulatory factors (IRF) and induction of type I interferons and interferon-stimulated genes (ISGs). In turn, ISGs not only display a variety of antiviral actions inside infected cells but also boost inflammatory responses as a result of paracrine activation through the JAK-STAT signaling pathway [10]. Altogether, the upregulation of ISGs has been termed the interferon "signature" (Fig. 1).

Epidemiological data has revealed a geographical clustering and defined seasonal epidemics of anti-MDA5-positive CADM cases [11], which supports the role of environmental factors, possibly RNA virus infections, in the development of the disease.

![Fig. 1 Role of MDA5 in cells. MDA5/RIG-I molecules act as sensors of viral RNA activating the interferon pathway by means of MAVS aggregation from monomeric filaments. The next step is the activation of the JAK-STAT pathway generating an inflammatory state that helps to clear the virus but also can trigger an autoimmune disease. ISG, interferon-stimulated genes; MAVS, mitochondrial antiviral signaling; MDA5, melanoma differentiated gene 5 protein]
Intriguingly, the pulmonary phenotype of zoonotic coronaviruses, including Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and SARS-CoV-2, the etiologic agent of the current COVID-19 pandemic, resemble that of patients with anti-MDA5 CADM-associated RP-ILD. Patients infected with these airborne transmitted viruses are at risk of developing severe pneumonia and adult distress respiratory syndrome (ADRS). Notably, not only the cytokine profiles but also chest computed tomography scans show striking similarities [12]. Moreover, due to its long size and 5′ capped structure, SARS-CoV-2 is predicted to primarily interact with the MDA5 cytosolic receptor, being the latter probably involved in the innate response against COVID-19 [13]. Nevertheless, none of our SARS-CoV-2-infected patients who developed ADRS tested positive for anti-MDA5 antibodies (personal communication).

The lack of MDA5/IFIH1 cytoplasmic RNA sensor in pangolins (mammalian order Pholidota), an intermediate host for different species of coronavirus and identified as a possible source of SARS-CoV-2, could prevent the innate immune response in these animals against the coronavirus and may explain why they tolerate the infection without developing a severe inflammatory state, as is the case in human beings [14, 15]. Altogether, these findings raise intriguing questions about the role of viruses and its consequences, the autoimmune/inflammatory reaction, in anti-MDA5 syndrome etiopathogenesis [16, 17].

**Pharmacologic treatment and its rationale**

**Immunosuppressive drugs**

The first line of treatment in patients with anti-MDA5 CADM patients with RP-ILD includes several types of immunosuppressive agents. A recent review focused on evidence-based therapeutic recommendations [18••] suggests that the best initial approach to manage these patients is a combined treatment using various immunosuppressive drugs, being the first options either a combination of glucocorticoids and a calcineurin inhibitor (cyclosporine or tacrolimus) or a triple therapy adding intravenous cyclophosphamide to the other two drugs.

This combined strategy is supported by several recent reports [19, 20, 21•], including a multicenter prospective study [21•] from Japan. In this study, a total of 29 adult Japanese patients with new-onset anti-MDA5-positive dermatomyositis and ILD were enrolled from 2014 to 2017 and treated with a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus, and intravenous cyclophosphamide. The 6-month survival of the patients who received this combined therapy was significantly higher than the patients who received a step-up strategy starting with high-dose glucocorticoids followed by stepwise addition of other immunosuppressants (89% vs 33%; p < 0.0001).

These findings were replicated in a retrospective observational study [20], also from Japan, which included 11 patients with anti-MDA5-positive
CADM and RP-ILD who were treated early with a combination of high-dose glucocorticoids, i.v. cyclophosphamide and tacrolimus, experiencing a significant improvement in their pulmonary forced vital capacity. Even though this study did not have a control group, no differences in mortality were observed when comparing patients with other dermatomyositis phenotypes (e.g., anti-synthetase or anti-TIF1γ). As a potential drawback of this approach, the authors alerted of frequent cytomegalovirus reactivations induced by the profound immunosuppression of the patients.

In those patients where calcineurin inhibitors are not tolerated (e.g., severe hypertension or difficult to manage diabetes), other immunosuppressants such as mycophenolate mofetil or biologic therapies such as the anti-CD20 humanized monoclonal antibody rituximab [22–24] should be considered.

Other drugs or biological therapies have also shown promising results, including basiliximab [25], an anti-CD25/sIL-2R monoclonal antibody, or tofacitinib [26, 27, 28•, 29–31] (a Janus kinase 1/3 inhibitor). Considering the proposed physiopathology of the anti-MDA5 syndrome, the JAK/STAT system is a particularly attractive therapeutic target in the anti-MDA5 syndrome, since not only type I and II interferons but also additional proinflammatory cytokines, including IL6, are involved in this pathway.

Specifically, two studies addressed the role of tofacitinib for the treatment of the RP-ILD in anti-MDA5-positive CADM patients. The first study [26] included a case series of 5 patients who received tofacitinib at a dose of 10 mg/day after failed to respond to a triple therapy with high-dose glucocorticoids, cyclosporine, and cyclophosphamide. The authors compared the outcomes of these 5 patients with 6 historical patients who had been treated with triple therapy without tofacitinib. Both groups of patients were comparable regarding major factors of poor prognosis, including high serum ferritin levels, worsening pulmonary infiltrates, and generalized ground-glass opacities. Of note, three of the tofacitinib group had a favorable response, while the rest, including all patients from the historical cohort, died. Alternatively, cytomegalovirus reactivation was constant in patients who received triple therapy and tofacitinib. The second study [28•], from China, was an open-label clinical study from a single-center evaluating the efficacy of tofacitinib at the early stages of anti-MDA5-positive CADM-associated ILD. From July 2017 to September 2018, a total of 18 consecutive patients were enrolled and received treatment mostly with glucocorticoids and tofacitinib (5 mg/12 h) and only occasionally with other immunosuppressants (2 patients received cyclosporine, and 1 mycophenolate mofetil). When compared with a historical control group of 25 patients treated with a step-wise immunosuppressive approach based on cyclosporine, mycophenolate mofetil, and/or cyclophosphamide, the survival at 6 months was significantly higher in the group treated with tofacitinib than in the historical control group. An issue to note in this study was that patients achieved a favorable outcome in the absence of severe immunosuppression, which helped to avoid infectious complications such as cytomegalovirus reactivation, or other fastidious opportunistic infections.
Genetic background in anti-MDA5 therapeutics

The recent identification of new myositis-associated genome-wide loci [32–34] may help to improve our capacity to identify potential targets for therapeutics. This could be the case of the gene product TYK2 which is targeted by tofacitinib, FAM167A-BLK targeted by nintedanib, or the truncated WDFY4 gene in Japanese patients, which enhances the MDA5-mediated nuclear-factor kappa B (NF-kB) activation in a calcineurin-dependent fashion.

How to identify the best therapeutic strategy?

The best strategy to achieve a good outcome in patients with anti-MDA5-positive CADM-associated RP-ILD seems to be to start a combined immunosuppressive therapy as soon as possible. It is nonetheless challenging to identify at the very onset of the disease those patients who are at risk of suffering an RP-ILD. As mentioned above, there are several predictive factors, including the presence of high ferritin plasma levels (approx. cutoff of 1000 ng/ml, NV < 200 ng/ml) [35, 36], worsening of the pulmonary infiltrates despite treatment, and generalized ground-glass opacities, which are considered as reliable poor prognosis markers [26]. Other factors such as the serologic levels of Krebs von den Lungen-6 (KL-6) or the titer of anti-MDA5 antibodies could also be of value, albeit they are currently mostly used in research settings [37, 38].

Thus, although there are reported early diagnosis strategies and therapeutic algorithms (see Figs. 2 and 3), it is still the treating clinician who has to decide whether or not to initiate a combined immunosuppressive therapy in an individual patient.

While the diagnosis of ILD relies on chest X-ray and/or high-resolution CT scans showing reticular opacities, ground-glass opacity or a honeycombing appearance, rapidly progressive ILD should be considered in cases of worsening of radiologic interstitial changes with progressive dyspnea and hypoxemia within 1 month after the onset of the respiratory symptoms [39, 40].

Pirfenidone and nintedanib, both drugs approved for the treatment of idiopathic pulmonary fibrosis [40], may be useful to some extent in the treatment of the anti-MDA5-positive CADM-associated RP-ILD patients. The first one, pirfenidone, was evaluated in a recent study from China which reported the outcome of 30 patients diagnosed with CADM-RP-ILD receiving 1800 mg/day in addition to conventional treatment with glucocorticoids and other immunosuppressive drugs. Although the drug had no impact on survival in the acute-fulminant forms, it was proven useful in the more subacute presentation. Thus, the administration of pirfenidone might play a role in improving the long-term outcome in those patients who survive [41]. Similarly, nintedanib, an intracellular inhibitor of tyrosine kinases, has demonstrated its utility not only in patients with idiopathic pulmonary fibrosis [42], but also in patients with ILD secondary to systemic sclerosis [43], and more importantly, in different diseases with ILD and a progressive course to lung...
fibrosis [44•]. In general, those patients who survive to the acute/fulminant form of ILD, but who may develop ILD fibrosis as a long-term manifestation, might benefit from those antifibrotic drugs. Multicenter prospective studies gathering a high number of patients may be necessary to determine the utility of these particular treatments in anti-MDA5 patients with RP-ILD.

**Refractory patients**

Most experts agree on defining a refractory patient as the one that does not respond to either of the two main modalities of therapy (prednisone plus calcineurin antagonists or prednisone plus cyclophosphamide plus calcineurin antagonists). Alternatively, the absence of response is defined when 1 week after the onset of the combination therapy the patient fulfills the following criteria: worsening of the respiratory symptoms (dyspnea), increasing alveolar-arterial $O_2$ tension difference, newly emerging or expanding GGO/consolidation on chest imaging, increasing ferritin levels, and the personal impression of clinical worsening as assessed by the attending physicians. In this scenario, adding a new immunosuppressive drug (mycophenolate mofetil, rituximab, basiliximab, or tofacitinib) or switching one immunosuppressant for another are both reasonable options, emphasizing the use
of the Janus kinase inhibitor tofacitinib according to the very latest studies, although the evidence is still scarce and of low quality.

Other non-pharmacologic alternative rescue therapies in these severe cases include using plasmapheresis, polymyxin B hemoperfusion, intravenous immunoglobulins, veno-venous extracorporeal membrane oxygenation (VV-ECMO), and lung transplantation.

**Plasmapheresis**

Also known as therapeutic plasma exchange, plasmapheresis (PMF) is a procedure in which blood passes through a device allowing to separate or remove some molecules from the plasma [45]. Its rationale in anti-MDA5-positive CADM RP-ILD patients is to remove the anti-MDA5 antibodies and to absorb or eliminate cytokines or other inflammatory molecules. The reported role of several cytokines, including the IL-6, IL-10, and IL-18 in the pathophysiology of MDA5-associated RP-ILD, supports the potential utility of plasmapheresis in these patients. Moreover, plasmapheresis can be used even if there is a concurrent infectious disease, which is not unusual in severely immunosuppressed patients. Even though a recent study about therapeutic recommendations in anti-MDA5 patients plasmapheresis was categorized as a level 3 of evidence (efficacy based in case reports and case series), it was recommended as a therapeutic option for refractory patients [18••].

---

*Fig. 3* Treatment algorithm for RP-ILD patients with anti-MDA5 antibodies (see ref. [18••])
During the last year, several reports reinforced the role of plasmapheresis in anti-MDA5-positive CADM RP-ILD patients. In brief, Shirakashi et al. from Japan retrospectively analyzed a cohort of 13 anti-MDA5-positive dermatomyositis patients with RP-ILD, all of them refractory to combined immunosuppressive therapy with glucocorticoids, calcineurin inhibitors, and intravenous monthly cyclophosphamide pulses. Five out of eight patients who received plasmapheresis as an add-on therapy survived, in comparison with none of the 5 patients who were treated only with combined immunosuppressive therapy without plasmapheresis [46]. Similarly, another study performed also in Japan [47•] reported 10 anti-MDA5-positive CADM RP-ILD patients with combined immunosuppressive therapy refractory disease. While six of them were additionally treated with plasmapheresis and were all alive at 1 year, only 25% of the ones who did not receive plasmapheresis survived.

Some other examples are supporting the possible benefit of plasmapheresis as an additional therapy in patients with refractory disease [48–51]. Nevertheless, the variety of local protocols and fluid replacement regimes used might yield different results and bias the evaluation of the efficacy of this procedure. Furthermore, transfusion-related acute lung injury following plasma exchange sessions is an infrequent but potentially threatening complication of this treatment [52].

Globally, plasmapheresis could be considered an effective adjuvant therapy in refractory anti-MDA5-positive CADM RP-ILD patients.

### Polymyxin-B hemoperfusion

The rationale for using polymyxin B-immobilized fiber column direct hemoperfusion treatment is similar to plasmapheresis, functioning as an extracorporeal blood filter that absorbs blood molecules, including toxins, proteins, or antibodies, although the underlying mechanisms remain still unclear. This technique has been recommended for the treatment of refractory septic shock with multiorgan dysfunction and endotoxinemia [53] and also an alternative therapy for patients with acute respiratory distress syndrome [54]. Several case reports and case series [55–60] support using this technique as adjuvant therapy in anti-MDA5-positive CADM-associated RP-ILD patients refractory to combined immunosuppressive therapy. An expert panel included that polymyxin B-immobilized fiber column direct hemoperfusion may be an alternative rescue treatment in patients who do not respond to combined immunosuppressive drugs, either separately or sequentially with plasmapheresis [18••].

### Veno-venous extracorporeal membrane oxygenation (ECMO)

Veno-venous extracorporeal membrane oxygenation (ECMO) is a life-support technique aimed to maintain blood oxygenation in patients with severe respiratory failure. Thus, it applies to anti-MDA5-positive CADM-associated RP-ILD patients refractory to combined immunosuppressive therapy, mostly as a
bridge to a most definitive solution like lung transplantation or while waiting for a response to the immunosuppressive drugs. Currently, there is scarce data on the efficacy of VV-ECMO in this type of patients [61, 62•, 63–68, 69•, 70], and was considered successful only in a few patients, either because it helped to improve the clinical status of the patient or it allowed performing a lung transplantation [67, 68, 69•, 70].

**Lung transplantation**

According to recent data, patients diagnosed with connective tissue diseases and interstitial lung involvement are not worse candidates for lung transplantation than those with non-connective tissue diseases [71]. Notwithstanding this, our personal experience with lung transplantation in patients with anti-MDA5-associated RP-ILD has not been encouraging. A series of three patients underwent lung transplantation in our center and all three died during the first year of follow-up. Chronic rejection, graft dysfunction, and opportunistic infections were respectively responsible for these deaths (personal communication) [72]. It is noteworthy that none of the potential specific challenges related to transplant in patients with the anti-MDA5 syndrome, including subclinical myocardial involvement, muscle weakness-induced hypoventilation, gastroesophageal reflux disease, dysphagia, malignancy, and relapse of the underlying disease, was observed in our patients. Alternatively, the fact that the three of our patients underwent transplantation as an emergency surgery might have largely contributed to the poor outcomes [73].

There is an additional experience of lung transplants reported by other authors [67, 68, 69•, 70, 74] including a total of 7 patients, all of them survived. Thus, lung transplantation is a viable therapeutic option in refractory patients with anti-MDA5-associated RP-ILD. Referring those patients to centers with experience evaluating and managing lung transplants is strongly recommended [18••].

**Conclusions**

The pharmacological treatment of patients with anti-MDA5-positive CADM-associated RP-ILD is a medical challenge. Currently, early combined double or triple immunosuppressive therapy with glucocorticoids plus calcineurin inhibitors with or without cyclophosphamide is the preferred therapeutic option followed by the use of mycophenolate mofetil or rituximab when calcineurin antagonists are not feasible. In refractory patients, adding one more immunosuppressive drug (mycophenolate mofetil, rituximab, basiliximab, or tofacitinib) to the current therapy or changing one immunosuppressant for another are both reasonable options. Based on its mechanism of action and recent reports, the JAK inhibitor tofacitinib may be considered a new promising agent, although further data in RP-ILD are warranted to prioritize it in the current therapeutic algorithm. Finally, although the specific pathogenesis
of the RP-ILD in the anti-MDA5 syndrome is still unknown, more data on
the genetic background, environmental triggers, and risk and prognostic fac-
tors may contribute to identifying patient profiles that will hopefully help to
define the best patient-tailored therapy.

Funding
This work was supported in part by the Instituto de Salud Carlos III and the European Regional Develop-
ment Fund (ERDF) (grant number P115/02100).

Declarations

Conflict of Interest
A. Selva-O’Callaghan declares that he has no conflict of interest. F. Romero-Bueno declares that he has no
conflict of interest. E. Trallero-Araguás declares that he has no conflict of interest. A. Gil-Vila declares that
he has no conflict of interest. J. C. Ruiz-Rodríguez declares that he has no conflict of interest. O. Sánchez-
Pernaute declares that he has no conflict of interest. I. Pinal-Fernández declares that he has no conflict of
interest.

Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

1. ** Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-
Araguas E, Milisenda JC, Grau- Junyent JM, Mammen AL. Classification and management of
adult inflammatory myopathies. Lancet Neurol. 2018;17:816–28. A comprehensive classification of
adult inflammatory myopathies and its management is herein reported. Myositis-specific autoantibodies
associated with characteristic clinical phenotypes, as is the case of anti-MDA5 clinical amyopathic der-
matomyositis, are underlined.
2. Connors GR, Christopher-Stine L, Oddis CV, Danoff
SK. Interstitial lung disease associated with the
idiopathic inflammatory myopathies: what pro-
gress has been made in the past 35 years? Chest.
2010;138(6):1464–74.
3. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies
to a 140-kd polypeptide, CADM-140, in Japanese
patients with clinically amyopathic dermatomyositis.
Arthritis Rheum. 2005;52:1571–6.
4. Chen Z, Cao M, Plana MN, et al. Utility of anti-mel-
anoma differentiation-associated gene 5 antibody
measurement in identifying patients with dermato-
myositis and a high risk for developing rapidly
progressive interstitial lung disease: a review of the
literature and a meta-analysis. Arthritis Care Res
(Hoboken). 2013;65:1316–24.
5. Labrador-Iorrillo M, Martinez MA, Selva-
O’Callaghan A, et al. Anti-MDA5 antibodies in a
large Mediterranean population of adults with der-
matomyositis. J Immunol Res. 2014;2014:290797.
https://doi.org/10.1155/2014/290797. Epub 2014
Feb 4. PMID: 24741583; PMCID: PMC3987881.
6. Allenbach Y, Uzunhan Y, Toquet S, et al. Different
phenotypes in dermatomyositis associated with
anti-MDA5 antibody: study of 121 cases. Neurology.
2020;95:e70–8.
7. Li Y, Gao X, Li Y, et al. Predictors and mortality of
rapidly progressive interstitial lung disease in
patients with idiopathic inflammatory myopathy: a
series of 474 patients. Front Med (Lausanne).
2020;7:363. https://doi.org/10.3389/fmed.2020.
00363. Published 2020 Jul 31.
8. Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-
melanoma differentiation-associated protein
5-associated dermatomyositis: expanding the
clinical spectrum. Arthritis Care Res (Hoboken).
2013;65:1307–15.
9. Wang DP, Zhang HY, Liao BW, et al. SRP54 Negatively regulates IFN-beta production and antiviral response by targeting RIG-I and MDA5 [published online ahead of print, 2020 Aug 7]. Virol Sin. 2020. https://doi.org/10.1007/s12250-020-00267-6.

10. Rice GI, Park S, Gavazzi F, et al. Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. Hum Mutat. 2020;41:837–49.

11. Muro Y, Sugiuira K, Hoshino K, Akiyama M, Tamakoshi K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther. 2011;13:R214.

12. Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014;53:2196–203.

13. Gao H, Yao H, Yang S, Li L. From SARS to MERS: evidence and speculation. Front Med. 2016;10:377–82.

14. Fischer H, Tschachler E, Eckhart L. Pangolins lack IFIH1/MDA5, a cytoplasmic RNA sensor that initiates innate immune defense upon coronavirus infection. Front Immunol. 2020;11:939.

15. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

16. Giannini M, Ohana M, Nespola B, et al. Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J. 2020;in press. https://doi.org/10.1183/13993003.01618-2020.

17. Xu Q. MDA5 should be detected in severe COVID-19 patients [published online ahead of print, 2020 May 28]. Med Hypotheses. 2020;143:109890.

18. Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020;50:776–90. A task force of expert panel from different specialties developed a set of evidence-based recommendations for the treatment of this severe condition. Combined immunosuppressive therapy and several rescue therapies were considered.

19. Koga T, Kaieda S, Okamoto M, et al. Successful treatment of rapidly progressive unclassifiable idiopathic interstitial pneumonia with anti-melanoma differentiation-associated gene-5 antibody by intensive immunosuppressive therapy. Intern Med. 2018;57:1039–43.

20. Matsuda KM, Yoshizaki A, Kuzumi A, et al. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. J Dermatol. 2020;47:483–9.

21. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72:488–98. This multicenter and prospective study showed that combined immunosuppressive therapy which includes high-dose glucocorticoids, tacrolimus, and intravenous cyclophosphamide plus plasmapheresis as a rescue therapy was effective in anti-MDA5-positive DM patients.

22. Koichi Y, Aya Y, Megumi U, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2017;27:536–40.

23. Ogawa Y, Kishida D, Shimojima Y, Hayashi K, Sekijima Y. Effective Administration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review. Case Rep Rheumatol. 2017;2017:5386797. https://doi.org/10.1155/2017/5386797. Epub 2017 Oct 31. PMID: 29225988; PMCID: PMC5684540.

24. Tokunaga K, Hagino N. Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan. Intern Med. 2017;56:1399–403.

25. Zou J, Li T, Huang X, Chen S, Guo Q, Bao C. Basi-leximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis. 2014;73:1591–3.

26. Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018;57:2114–9.

27. Kato M, Ikeda K, Kagayama T, et al. Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis. J Clin Rheumatol. 2019 Jan 4. https://doi.org/10.1097/RHU.0000000000000984. Epub ahead of print. PMID: 30614890.

28. Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381:291–3. In an open-label clinical study, patients who received tofacitinib, a JAK inhibitor, at the early stages of anti-MDA5-positive dermatomyositis-associated interstitial lung disease, achieve a significant higher 6-month survival than a cohort of historical controls.
Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive ... Selva-O’Callaghan et al. 331

29. Takatani A, Koga T, Fujita Y, et al. Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis. Clin Immunol. 2020;215:108451.

30. Ohmura SI, Yamabe T, Naniwa T. Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies. Mod Rheumatol Case Rep. 2021;5:76–81.

31. Kato M, Ikeda K, Kageyama T, et al. Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis. J Clin Rheumatol. 2019. https://doi.org/10.1097/RHU.0000000000000984.

32. Acosta-Herrera M, Kerick M, González-Serna D, et al. Genome-wide meta-analysis reveals shared new loci risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. 2018;77:602–11.

33. Kochi Y, Kamatani Y, Kondo Y, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. 2018;77:602–11.

34. Rothwell S, Cooper RG, Lundberg IE, et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis. 2019;78:311–9.

35. Gono T, Kawaguchi Y, Ozeki E, et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 2011;21:223–7.

36. Nishioka A, Tsunoda S, Abe T, et al. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Mod Rheumatol. 2019;29:814–20.

37. Matsushita T, Mizumaki K, Kano M, et al. Anti-melanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176:395–402.

38. Sakamoto S, Okamoto M, Kaieda S, et al. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Respir Investig. 2018;56:464–72.

39. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–68.

40. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

41. Li T, Guo L, Chen Z, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. 2016;6:33226.

42. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis [published correction appears in N Engl J Med. 2015 Aug 20;373(8):782]. N Engl J Med. 2014;370(22):2071–82.

43. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518–28.

44. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–27. Nintedanib, an antifibrotic agent, halted the progression of interstitial lung disease of different etiologies in a double-blind, placebo-controlled trial. Patients with myositis-associated interstitial lung diseases were not included in this study but antifibrotic drugs might play a role for interstitial lung disease improvement in anti-MDA5-positive dermatomyositis patients.

45. Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164:342–51.

46. Shirakashi M, Nakashima R, Tsuji H, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment [published online ahead of print, 2020 Apr 10]. Rheumatology (Oxford). 2020;kea123. https://doi.org/10.1093/rheumatology/kea123.

47. Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology (Oxford). 2020;59:767–71. Therapeutic plasma exchange may play a role as a rescue therapy in anti-MDA5-positive refractory interstitial disease. In this article, the authors report their experience in a series of 10 patients who were refractory to combined immunosuppressive therapy.

48. Ning Y, Yang G, Sun Y, Chen S, Liu Y, Shi G. Efficiency of therapeutic plasma-exchange in acute interstitial lung disease, associated with polymyositis/dermatomyositis resistant to glucocorticoids and immunosuppressive drugs: a retrospective study. Front Med (Lausanne). 2019;6:329.

49. Endo Y, Koga T, Suzuki T, et al. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: a case report. Medicine (Baltimore). 2018;97:e0436.

50. Saito T, Mizobuchi M, Miwa Y, et al. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a
51. Yamagata A, Arita M, Tanaka A, et al. Therapeutic plasma exchange for clinically amyopathic dermatomyositis (CADM) associated with rapidly progressive interstitial pneumonia [published online ahead of print, 2020 Aug 18]. J Clin Apher. 2020;https://doi.org/10.1002/jca.21833.

52. Kagawa H, Tsujino K, Yamamoto Y, et al. Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease. A case report. Respir Med Case Rep. 2020;29:101016.

53. Klein DJ, Foster D, Walker PM, Bagshaw M, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxia: a post hoc analysis of the EUPHirates trial. Intensive Care Med. 2018;44:2205–12.

54. Tsushima K, Kubo K, Koizumi T, et al. Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome. J Clin Apher. 2002;17:97–102.

55. Okabayashi H, Ichiyasu H, Hirooka S, Akaike K, Kojima K, Jodai T, et al. Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias. BMC Pulm Med. 2017;17:134.

56. Sasaki O, Doi M, Harada H, et al. A case of polymyxin B-immobilized fiber column treatment for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis. Case Rep Med. 2013;2013:750275.

57. Teruya A, Kawamura K, Ichikado K, Sato S, Yasuda Y, Yoshioka M. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest. 2013;144:1934–6.

58. Furusawa H, Sugiuara M, Mitaoka C, Inase N. Direct hemoperfusion with polymyxin B-immobilized fibre treatment for acute exacerbation of interstitial pneumonia. Respiratory. 2017;22:1357–62.

59. Ichiyasu H, Horio Y, Tsumura S, Hirotaka S, Sakamoto Y, Sakata S, et al. Favorable outcome with hemoperfusion of polymyxin B-immobilized fiber column for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of three cases. Mod Rheumatol. 2014;24:361–5.

60. Ichiyasu H, Horio Y, Masunaga A, Migiyma Y, Sakamoto Y, Jodai T, et al. Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMXDHFP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies. Ther Adv Respir Dis. 2017;11:261–75.

61. Broome M, Palmer K, Schersten H, Frenchnier B, Nilsson F. Prolonged extracorporeal membrane oxygenation and circulatory support as bridge to lung transplant. Ann Thorac Surg. 2008;86:1357–60.

62. Vuillard C, Pineton de Chambrun M, de Prost N, Guerin C, Schmidt M, Dargent A, et al. Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermatomyositis. French multicenter retrospective study. Ann Intensive Care. 2018;8:87.

63. Gorka J, Szczeklik W, Wludarczyk A, Loboda P, Chmura L, Musial J. Rapidly progressive interstitial lung fibrosis in a patient with amyopathic dermatomyositis and anti-MDA5 antibodies. Pol Arch Med Wewn. 2015;125:685–6.

64. Aoyama J, Hayashi H, Yajima C, et al. Anti-MDA-5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations. Respir Med Case Rep. 2019;26:193–6.

65. Li ZY, Gill E, Mo F, Reyes C. Double anti-PL-7 and anti-MDA-5 positive amyopathic dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient. BMC Pulm Med. 2020;20:220.

66. Leclair V, Labirua-Iturburu A, Lundberg IE. Successful lung transplantation in a case of rapidly progressive interstitial lung disease associated with antimelanoma differentiation-associated gene 5 antibodies. J Rheumatol. 2018;45(4):581–3.

67. Deitchman AR, Kalchiem-Dekel O, Todd N, Reed RM. Rapidly progressive interstitial lung disease due to anti-melanoma differentiation associated protein-5 requiring a bilateral lung transplant, and complicated by kennel cough. Respir Med Case Rep. 2019;28:100886.

68. Huang K, Vinik O, Shojiangia K, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int. 2019;39:1971–81. In this cohort of patients with anti-MDA5-positive dermatomyositis from Canada, three patients underwent a successful lung transplantation. Lung transplantation may be a life-saving therapy in refractory cases
of anti-MDA5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.

70. Pacot L, Pouchot J, De Prost N, et al. Interstitial lung disease-complicated anti-MDA5 antibody in clinically amyopathic dermatomyositis patients: report of two cases with distinct clinical features. Front Med (Lausanne). 2020;7:77.

71. Prieto-Peña D, Martínez-Meñaca A, Calderón-Goercke M, et al. Long-term survival of lung transplantation for interstitial lung disease associated with connective tissue diseases: a study of 26 cases from a referral centre. Clin Exp Rheumatol. 2020;38:615–20.

72. Selva-O’Callaghan A, Labrador-Horrillo M, Munoz-Gall X, et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus. 2005;14:534–42.

73. Dotan Y, Vaidy A, Shapiro WB, Zhao H, Dass C, Toyoda Y, et al. Effect of acute exacerbation of idiopathic pulmonary fibrosis on lung transplantation outcome. Chest. 2018;154:818–26.

74. Shoji T, Bando T, Fujinaga T, et al. Living-donor lobar lung transplantation for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of a case. Gen Thorac Cardiovasc Surg. 2013;61:32–4.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.